SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Black D. Report From the Fifth International Symposium on Recent Clinical Advances in Osteoporosis, International Symposium on Recent Clinical Advances in Osteoporosis. Honolulu, Hawaii; 2002.
  • 2
    Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997; 103: 12S9.
  • 3
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al, and the Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 153541.
  • 4
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 207782.
  • 5
    Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157: 261724.
  • 6
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide (recombinant human parathyroid hormone 1–34) with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 452835.
  • 7
    Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103: 298307.
  • 8
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 65361.
  • 9
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 143441.
  • 10
    Kanis JA, Johnell O, Oden A, Dawson A, de Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 98995.
  • 11
    Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 103: 74S89S.
  • 12
    Greenfield S, Kaplan S, Ware JE Jr. Expanding patient involvement in care: effects on patient outcomes. Ann Intern Med 1985; 102: 5208.
  • 13
    Edworthy SM, Devins GM, and the Patient Education Study Group. Improving medication adherence through patient education distinguishing between appropriate and inappropriate utilization. J Rheumatol 1999; 26: 1793801.
  • 14
    Daltroy LH. Doctor-patient communication in rheumatological disorders. Baillieres Clin Rheumatol 1993; 7: 22139.
  • 15
    Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 24149.
  • 16
    Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis Int 2001; 12: 51928.
  • 17
    National Osteoporosis Foundation. About osteoporosis. URL: www.nof.org/osteoporosis/index.htm.
  • 18
    Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 2004; 63: 13728.
  • 19
    Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004; 164: 1299304.
  • 20
    Fraenkel L, Bodardus S, Wittnik DR. Understanding patient preferences for the treatment of lupus nephritis with adaptive conjoint analysis. Med Care 2001; 39: 120316.
  • 21
    Johnson RM. Adaptive conjoint analysis. Sawtooth Software Conference Proceedings: Ketchum (ID); 1987. p. 25365.
  • 22
    Wittink DR, Bergenstuen T. Forecasting with conjoint analysis. In: ArmstrongJS, ed. Principles of forecasting: a handbook for researchers and practitioners. Norwell (MA): Kluwer Academic Publishers; 2001.
  • 23
    Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 15303.
  • 24
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health status survey manual. Boston: The Health Institute, New England Medical Center; 1993.
  • 25
    Ganther JM, Wiederholt JB, Kreling DH. Measuring patients' medical care preferences: care seeking versus self-treating. Med Decis Making 2001; 21: 13340.
  • 26
    Janis IL, Mann L. Decision-making: a psychological analysis of conflict, choice, and commitment. New York: The Free Press; 1985.
  • 27
    Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Mark 1990; 54: 317.
  • 28
    Braddock CH 3rd, Edwards KA, Hasenberg NM, Laidley TL, Levinson W. Informed decision making in outpatient practice: time to get back to basics. JAMA 1999; 282: 231320.
  • 29
    Rothman AJ, Kiviniemi MT. Treating people with information: an analysis and review of approaches to communicating health risk information. J Natl Cancer Inst Monogr 1999; 25: 4451.
  • 30
    Gigerenzer G. Calculated risks. New York: Simon & Schuster; 2002.